Nigeria tries cheaper Aids drugs

DonateNow
Print this article

Nigeria tries cheaper Aids drugs

BBC News - Monday, 10 December, 2001
Dan Isaacs in Lagos


A highly publicised new anti-Aids programme in Nigeria has got off to a poor start because hospitals due to begin distributing cheap imported generic drugs have not yet received their supplies.

Over the coming months, 10,000 patients are due to be treated with anti-retroviral drugs imported from India.

Recent figures published by the Ministry of Health indicate that almost 3.5 million Nigerians are believed to be infected with the HIV virus.

But there is considerable doubt whether such a generic drugs programme is the most appropriate way to tackle HIV infection in Nigeria.

The Nigerian experiment in tackling the Aids pandemic will be closely observed across Africa.

Prevention urged

Nigerian President Olusegun Obasanjo has strongly endorsed the trials.

However, critics of the programme have questioned the ability of the country's poorly managed health system to cope with the close monitoring of patients required during the administering of the anti-HIV drugs.

Moreover, critics argue that whatever resources are available should be put into HIV prevention.

But those in favour of the trials point to the widespread use of similar but much more costly drugs in Europe and the United States and ask why Africans should be deprived of the chance to live a longer, healthier life despite HIV infection.

Multinational drug companies have strongly opposed the sale of generic copies of their own branded drugs, arguing that it reduces their profits and undermines their ability to invest in further research and development.

But following a court case in South Africa early this year, the argument for prohibiting developing countries from purchasing such generic drugs has been considerably weakened.

As for the Nigerian trials, there is already considerable doubt whether sufficient drugs have yet arrived in the country to stage an effective drugs programme.
011210
BB011214


Copyright © 2001 - BBC. Reproduction of this article (other than one copy for personal reference) must be cleared through the BBC.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.

.